Hereditary Transthyretin Amyloidosis (hATTR) is a rare, progressive, and life-threatening genetic disorder caused by mutations in the transthyretin (TTR) gene. This leads to the misfolding of TTR proteins, which accumulate as amyloid fibrils in various organs and tissues, disrupting their normal function. The most commonly affected organs include the peripheral nerves, heart, and gastrointestinal tract, leading to symptoms like peripheral neuropathy, cardiomyopathy, and gastrointestinal disturbances.

Hereditary Transthyretin Amyloidosis Market Insights

The global hATTR market has been experiencing significant growth due to increasing awareness, advances in diagnostic techniques, and the development of novel therapeutics. In recent years, several drugs have been approved that offer symptomatic relief and, in some cases, slow disease progression.

Key Hereditary Transthyretin Amyloidosis Companies In The Market Landscape:

Several hATTR companies such as Pfizer, Alnylam Pharmaceuticals, Akcea Therapeutics, Ionis Pharmaceuticals, AstraZeneca, Eidos Therapeutics, Corino Therapeutics, Prothena, Novo Nordisk, Intellia Therapeutics, Regeneron Pharmaceuticals, among others, are actively working in the Hereditary Transthyretin Amyloidosis (hATTR) Market.

Hereditary Transthyretin Amyloidosis Competitive Landscape

The competitive landscape of the hATTR market is characterized by the presence of several pharmaceutical companies actively engaged in research and development.

Alnylam Pharmaceuticals: A key player with its RNA interference (RNAi) therapeutic, Onpattro (patisiran), which has shown efficacy in reducing amyloid deposits and improving quality of life.

Pfizer: Tafamidis (Vyndaqel/Vyndamax) is another significant treatment that stabilizes the TTR protein, thereby slowing disease progression.

Ionis Pharmaceuticals and Akcea Therapeutics: Their collaborative effort led to the development of Tegsedi (inotersen), an antisense oligonucleotide that reduces TTR protein production.

Ongoing clinical trials and pipeline products from these and other companies aim to provide more comprehensive treatment options, targeting different mechanisms of disease progression.

Hereditary Transthyretin Amyloidosis Epidemiology

hATTR is a rare condition with an estimated prevalence of about 50,000 cases worldwide. It is more common in certain populations, such as those of Portuguese, Swedish, and Japanese descent. The disease typically manifests in adulthood, with a wide range of symptoms depending on the organs affected. Early diagnosis is crucial for effective management, yet remains challenging due to the variability in presentation.

Hereditary Transthyretin Amyloidosis Market Forecast

The hATTR market outlook is expected to grow significantly by 2030, driven by factors such as increasing diagnosis rates, advancements in treatment options, and ongoing research into novel therapeutics. With a projected compound annual growth rate (CAGR) of approximately 9-12%, the market is poised to expand as new treatments gain approval and more patients receive accurate diagnoses.

Conclusion:

Hereditary Transthyretin Amyloidosis presents significant challenges, but advancements in the understanding of its pathophysiology and treatment are transforming patient outcomes. The competitive landscape is dynamic, with major pharmaceutical companies investing heavily in R&D to bring forth innovative therapies. As awareness grows and diagnostic techniques improve, the market for hATTR therapeutics is set to expand, offering hope to those affected by this debilitating disease.

Latest Reports Offered By DelveInsight:

CDMO Market

Global CDMO market was valued at USD 100.02 billion in 2021, growing at a CAGR of 6.25% during the forecast period from 2024 to 2030, in order to reach USD 143.87 billion by 2030. Factors such as rising prevalence of various chronic and acute diseases leading to growing requirement of drugs, rising popularity of biologics as a treatment option are further expected to drive the demand for services offered by CDMOs as biologics being more complex than small molecules require elaborate facilities for product development.

Duchenne Muscular Dystrophy Market

DelveInsight's “Duchenne Muscular Dystrophy Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Duchenne Muscular Dystrophy historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Generalized Myasthenia Gravis Market

DelveInsight’s ‘Generalized Myasthenia Gravis Market Insights, Epidemiology, and Market Forecast—2032’ report delivers an in-depth understanding of the Generalized Myasthenia Gravis, historical and forecasted epidemiology as well as the market trends in the United States, EU-5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Glioblastoma Market

DelveInsight's "Glioblastoma Market Insights, Epidemiology and Market Forecast– 2032" report delivers an in-depth understanding of the Glioblastoma, historical and forecasted epidemiology as well as the Glioblastoma market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Sickle Cell Disease Market

DelveInsight's "Sickle Cell Disease Market Insights, Epidemiology and Market Forecast– 2032" report delivers an in-depth understanding of the Sickle Cell Disease, historical and forecasted epidemiology as well as the Sickle Cell Disease market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. Among the 6MM countries the Sickle cell disease market size was valued ~USD 650 million in 2023 and is expected to increase throughout the forecast period (2024-2034).

Holter Monitor Market

The Global Holter Monitor market will grow at a CAGR of 6.13% during the forecast period from 2024 to 2030. The stellar growth observed in the market is primarily due to the growing burden of various cardiovascular disorders which leads to abnormal heart rhythm such as atrial fibrillation, and heart palpitations, among others that may require monitoring through Holter monitors.